| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 25,479 | 25,459 | 16,791 | 4,048 | 3,269 |
| Sales Growth | +0.08% | +51.62% | +314.82% | +23.83% | +108.20% |
| Net Income | -2,844 | -3,618 | -8,743 | -14,735 | -16,775 |
| Net Income Growth | +21.38% | +58.62% | +40.67% | +12.16% | +48.95% |
Avicanna Inc (AVCN.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Avicanna Inc is a commercial-stage international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for the medical and pharmaceutical market segments. It has three operating segments: Canada, International, and Corporate. It generates the majority of its revenue from Canada.
Fiscal Year End Date: 12/31